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Background: Surveillance after orchiectomy has recently been a management option in patients with stage I
seminoma, while it remains controversial in those with stage I nonseminoma, and the risk factor associated with
relapse is still a matter of concern in both entities. This study was performed to explore pathological risk factors for
post-orchiectomy relapse in patients with stage I seminoma and nonseminoma, and to assess oncological
outcomes in those managed with surveillance.
Methods: In this single institution study, 118 and 40 consecutive patients with stage I seminoma and
nonseminoma were reviewed, respectively. Of the 118 patients with stage I seminoma, 56 and one received
adjuvant radiotherapy and chemotherapy, respectively, and 61 were managed with surveillance. Of the 40 men
with stage I nonseminoma, 4 underwent adjuvant chemotherapy and 36 were managed with surveillance.
Results: No patient had cause-specific death during the mean observation period of 104 and 99 months in men
with seminoma and nonseminoma, respectively. In men with stage I seminoma, 1 (1.7%) receiving radiotherapy and
4 (6.6%) men managed with surveillance had disease relapse; the 10-year relapse-free survival (RFS) rate was 93.4%
in men managed with surveillance, and their RFS was not different from that in patients receiving adjuvant
radiotherapy (logrank P=0.15). Patients with tunica albuginea involvement showed a poorer RFS than those without
(10-year RFS rate 80.0% vs. 94.1%), although the difference was of borderline significance (P=0.09). In men with
stage I nonseminoma, 9 (22.5%) patients experienced relapse. Patients with lymphovascular invasion seemingly had
a poorer RFS than those without; 40.0% and 18.7% of the patients with and without lymphovascular invasion had
disease relapse, respectively, although the difference was not significant (logrank P=0.17).
Conclusion: In both men with stage I seminoma and nonseminoma, surveillance after orchiectomy is a feasible
option. However, disease extension through tunica albuginea might be a factor associated with disease relapse in
patients with organ-confined seminoma, and those with stage I nonseminoma showing lymphovascular invasion
may possibly be at high risk for disease relapse.
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Testicular germ cell tumor is histopathologically classi-
fied into seminoma and nonseminomas, and nonse-
minomas are subclassified into embryonal carcinoma,
choriocarcinoma, yolk sac tumor, teratoma, and mixed
germ cell tumors. After an orchiectomy, the most feasible
therapeutic option is determined with risk assessment
based on the pathological diagnosis and clinical staging
[1]. Nonseminoma is more potent to metastasize and
lead to poorer prognosis compared with seminoma at
same stage. Surveillance has recently been a management
option in many patients with stage I seminoma, and
treatment and follow-up strategy vary according to the
clinicopathological characteristics in stage I nonse-
minoma [2,3]. However, risk factors associated with re-
lapse still remain controversial in both entities. This
study was performed to explore pathological risk factors
associated with disease relapse in men with stage I
seminoma and nonseminoma, and to evaluate onco-




This retrospective research project was approved by the
Ethics Committee of Niigata Cancer Center Hospital.
Written informed consent was obtained from all the pa-
tients. In total, 158 consecutive patients who were
treated for stage I testicular germ cell tumors at the De-
partment of Urology, Niigata Cancer Center HospitalTable 1 Patients’ demographics at diagnosis
Total (n=158) Seminoma (n=118)
age [y.o.] 37.0 ± 10.6 39.0 ± 9.8
mean ± SD (range) (1–65) (22–65)
side n(%) right 91 (57.6%) 70 (59.3%)
left 67 (42.4%) 48 (40.7%)
tumor size [cm] 6.0 ± 2.7 6.4 ± 2.8
mean ± SD (range) (1.5–18) (1.5–18)
pT n(%) T1 48 (30.4%) 32 (27.1%)
T2 63 (39.9%) 48 (40.7%)
T3 2 (1.3%) 2 (1.7%)
T4 1 (0.6%) 1 (0.8%)
Tx 44 (27.8%) 35 (29.7%)
LDH (IL/l) 449.8 ± 453.5 491.9 ± 504.9
mean ± SD (range) (121–3043) (112–3043)
AFP (ng/ml) 124.0 ± 801.7 2.9 ± 1.4
mean ± SD (range) (1.0–9363.1) (1.0–8.2)
hCGβ (ng/ml) 1.0 ± 1.8 0.9 ± 1.8
mean ± SD (range) (<0.1–10.9) (<0.1–10.9)
LDH, lactate dehydrogenase; AFP, α-fetoprotein, hCGβ, human chorionic gonadotrobetween May 1980 and December 2008 were enrolled in
the present study; 118 and 40 men were pathologically
diagnosed with seminoma and nonseminomas, respect-
ively. All of them received high orchiectomy. Disease
stage was determined with abdominal-pelvic computer-
ized tomography (CT) and thoracic CT or chest roent-
genography. Patients’ characteristics were presented in
Table 1; serum tumor markers such as lactate dehy-
drogenase (LDH), α-fetoprotein (AFP), and human
chorionic gonadotropin β subunit (hCGβ) had been nor-
malized after orchiectomy in all of them. Of the 118 pa-
tients with stage I seminoma, 56 received adjuvant
radiotherapy (para-aortic with or without ipsilateral pel-
vic irradiation of 28.9 Gy in 17 fractions), 61 were man-
aged with surveillance without adjuvant therapy, and
one underwent adjuvant chemotherapy.
Histopathological subtypes in the nonseminoma gro-
up were shown in Table 2. Rare histotypes potentially
coexistent with teratoma were not described [4]. Of
the 40 men with stage I nonseminomas, 4 underwent
cisplatin-based systemic chemotherapy and 36 were
managed surveillance without additional treatment. Fol-
low-up protocol was principally as follows: monthly
measurement of tumor markers and bimonthly or 3
monthly thoracic-abdominal-pelvic CT for the initial 6
months, 3-month interval measurement of tumor
markers and thoracic-abdominal-pelvic CT for the next
2 to 3 years, and 6- to 12-month interval examinations
for the next 5 to 10 years. The mean observation period
was 104 (range: 19 – 340) months in the seminomaNonseminoma (n=40) P value seminoma vs nonseminoma











323.6 ± 197.6 0.05
(121–945)
474.1 ± 1544.0 <0.01
(2.5–9363.1)
1.2 ± 1.7 0.37
(<0.1–6.69)
pin β subunit.
Table 2 Histological diagnosis in patients with
nonseminomas (n=40)
Pure 10 (25.0%)
Embryonal carcinoma 8 (20.0%)




Embryonal carcinoma 20 (50.0%)
York sac tumor 20 (50.0%)
Seminoma 19 (47.5%)
Choriocarcinoma 7 (17.5%)
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nonseminoma group.
Statistical analysis
In addition to the chi-square test for categorical vari-
ables, the Welsh-corrected t test was used to compare
unpaired continuous parameters among subgroups. Sur-
vival curves were generated using the method of Kaplan
and Meier, and they were compared using the logrank
test. Hazard ratio (HR) and 95% confidence interval (CI)
were calculated using the Cox proportional hazard
model. Statistical analyses were calculated and tested
using SPSS software version 15.0 (SPSS, Inc., Chicago,
IL, USA) and Prism Version 4.02 (GraphPad software,Table 3 Outcomes of patients with stage I seminoma
Radiation (n = 56)
Follow–up months






n (%) 1 (1.7%)
Site chest wall 1





Cause-specific death 0 (0%)
Death of other causes 4 (7.1%)
One patient receiving adjuvant chemotherapy was excluded.Inc., San Diego, CA, USA) for Windows-based com-
puters. The test was two-sided and P< 0.05 was consid-
ered significant.Results
Outcomes of patients with stage I seminoma
Table 3 shows outcomes in the seminoma group. In 80s
and 90s, 80.0% and 91.3% of the patients underwent ad-
juvant radiotherapy, respectively, whereas only 3.5% of
them experienced it in 2000s (P<0.001). In men receiv-
ing radiotherapy, 1 (1.7%) had disease relapse, and in
those managed with surveillance, 4 (6.6%) developed
metastasis (P=0.19). No patient had cause-specific death
in this group.
Both the 5-year and 10-year relapse-free survival rates
were 93.4% in men managed with surveillance, while
they were 98.2% in men receiving adjuvant radiotherapy.
Relapse-free survival was not different between patients
managed with surveillance and receiving radiotherapy
(P=0.15, Figure 1). We further examined the association
of patients or disease characteristics with oncological
outcomes (Table 4). None of the primary tumor size,
serum marker levels, pT stage, and radiotherapy was as-
sociated with disease relapse. Concerning pathological
characteristics, patients with tunica albuginea involve-
ment showed a poorer relapse-free survival than those
without, although the difference was of borderline sig-
nificance (logrank P=0.09, Figure 2).Surveillance (n = 61) P value
<0.01






























Figure 1 Relapse-free survival in patients with stage I



















Figure 2 Impact of tunica albuginea involvement on relapse-free
survival in patients with stage I seminoma.
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Of the 40 men with stage I nonseminoma, 36 (90%) were
managed with surveillance and 4 (10%) received adju-
vant chemotherapy after orchiectomy; patients’ charac-
teristics such as the tumor markers and size did not
differ between those with surveillance and adjuvant
chemotherapy (data not shown). In Table 5, outcomes of
the patients with stage I nonseminomas were summa-
rized. In this group, 9 (22.5%) patients had disease re-












Lymphovascular invasion No 37
Yes 51
Tunica albuginea involvement No 79
Yes 10
Spermatic cord invasion No 90
Yes 3
Radiotherapy No 61
Yes 56(25.0%) experienced disease relapse; in 8 of the 9 pa-
tients, disease relapsed in the retroperitoneum/para-
aortic lymph-nodes. None of the 4 patients who received
adjuvant chemotherapy developed relapsed tumors. All
of the 9 men with disease relapse were treated with
chemotherapy, and in 5 of them, surgical removal of tu-
mors was performed. No patient had cause-specific
death also in the nonseminoma group.
Both 5-year and 10-year relapse-free survival rates
were 77.5% in the nonseminoma group, and they weree in patients with stage I seminoma
Relapse Univariate analyses
n (%) P value HR 95%CI
1 (2.5%) 0.11 0.17 0.02-1.50
4 (8.3%) 1
2 (4.4%) 0.77 1.33 0.19-9.47
2 (3.4%) 1
2 (6.9%) 0.53 1.78 0.30-10.6
3 (4.0%) 1
1 (2.1%) 0.29 0.31 0.03-2.75
4 (8.0%) 1
2 (6.3%) 0.93 1.09 0.18-6.51
2 (3.9%) 1
3 (8.1%) 0.41 2.11 0.35-12.6
2 (3.9%) 1
3 (3.8%) 0.07 0.19 0.03-1.13
2 (20.0%) 1
5 (5.6%) - - -
0 (0%)
4 (6.6%) 0.23 3.83 0.43-34.3
1 (1.8%) 1
Table 5 Outcomes of patients with stage I nonseminomas
Surveillance Chemotherapy Total
(n=36) (n=4) (n=40)





Time to relapse (months) 2–13 (mean 6)




Cause-specific death 0 0 0
Death of other causes 1 1 2
Table 6 Influence of disease characteristics on relapse in
patients with nonseminomas
Variables No. Relapse Univariate analyses
n (%) p HR 95% CI
Age <40 30 7 (23.3%) 0.92 1.08 0.23-5.21
≥40 10 2 (20.0%) 1
Tumor size ≤5 cm 22 5 (22.7%) 0.88 0.90 0.21-3.75
>5 cm 12 3 (25.0%) 1
Embryonal carcinoma No 11 4 (36.4%) 0.21 2.31 0.62-8.60
Yes 28 5 (17.9%) 1
Choriocarcinoma No 32 8 (25.0%) 0.57 1.83 0.23-14.7
Yes 7 1 (14.3%) 1
Teratoma No 17 3 (17.6%) 0.49 0.62 0.15-2.46
Yes 22 6 (27.3%) 1
Yalk sac tumor No 19 3 (15.8%) 0.33 0.50 0.13-2.01
Yes 21 6 (28.6%) 1
AFP Normal 8 2 (25.0%) 0.93 0.93 0.19-4.49
Elevated 29 7 (24.1%) 1
βhCG Normal 13 4 (30.8%) 0.64 1.37 0.37-5.10
Elevated 23 5 (21.7%) 1
LDH Normal 20 6 (30.0%) 0.49 1.63 0.41-6.51
Elevated 16 3 (18.8%) 1
pT T1 16 3 (18.8%) 0.19 0.39 0.10-1.58
T2-4 15 6 (40.0%) 1
Lymphovascular invasion No 16 3 (18.8%) 0.19 0.39 0.10-1.58
Yes 15 6 (40.0%) 1
LDH, lactate dehydrogenase; AFP, α-fetoprotein, hCGβ, human chorionic
gonadotropin β subunit.
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amined the influence of disease characteristics on re-
lapse in patients with nonseminomas; the tumor size,
pathological subtypes, tumor marker levels, or pT stage
had no impact on disease relapse (Table 6). Regarding
disease invasiveness based on histopathological examina-
tions, patients with lymphovascular invasion seemingly
had poorer relapse-free survival than those without;
40.0% and 18.8% of the patients with and without
lymphovascular invasion had disease relapse, respec-
tively, although the difference was not significant
(P=0.17, Figure 3).
Discussion
Stage I testicular seminoma has been reported to relapse
between 10% and 20% in previous studies [5,6], while
adjuvant radiotherapy is frequently used with a relatively
encouraging outcome as relapse rates of 3–4% [7]. In
our institution, the overwhelming majority of men with
stage I seminoma have recently been managed with sur-
veillance (Table 3). In the current patient series managed
with surveillance, the 10-year relapse-free survival rate
reached 93.4%; it is speculated that diagnostic/staging
modalities such as high-performance CT might lead to
an appropriate exclusion of metastases and favorable
outcomes. Also, none of them died during the observa-
tion period; the prognosis of men with stage I testicular
seminoma is excellent when an appropriate surveillance
protocol is applied. However, their postorchiectomy
management remains a matter of concern, although ad-
verse events including treatment-associated morbidity is
less in adjuvant setting radiotherapy than in radical
chemotherapy for clinically recurrent disease. A few
previous studies tried to define risk-stratification of
testis-confined seminoma. Aparicio and associates pro-


















Figure 3 Impact of lymphovascular invasion on disease
relapse-free survival in patients with stage I nonseminoma.
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those with tumor diameter less than 4 cm and no rete
testis involvement were managed with surveillance; 6%
of these patients still experienced relapse [8]. In our
study, tumor burden, tumor markers, and pT were not
associated with disease relapse. Concerning pathological
characteristics, however, patients with disease extension
through tunica albuginea showed a poorer relapse-free
survival than those without. Although the difference was
not significant (P=0.09, Figure 2), 3.8% of the patients
without involvement of the tunica albuginea had relapse,
whereas the relapse rate reached 20% in those with
tunica albuginea involvement (Table 4). A recent retro-
spective study reported that tunica albuginea penetration
was predictive of the presence of metastasis (n=86,
P=0.00001), although the study recruited men with
seminoma at all stages [9]. To verify its significance in
risk-stratification of stage I seminoma, a high-volume
study based on cancer registry is currently underway.
It also remains controversial how patients with stage I
nonseminoma should be managed. Although cause-
specific death was absent in our patient series, it has
been fatal in 1% to 15% in previous reports [10-12].
Twenty-five to 30% of the patients with stage I
nonseminoma managed by surveillance have been
reported to experience disease relapse [7], and adjuvant
chemotherapy has been the therapeutic standard for
those with elevated tumor markers at diagnosis and/or
highly malignant histopathology [8,11]. Vascular invasion
and predominant embryonal carcinoma are generally
considered to be histopathologic risk factors [7]. In our
institution, men with stage I nonseminoma with normal-
ized tumor markers or markers showing reductions as-
sumed based on their half-life period are principally
managed with surveillance regardless of the mentioned
pathological characteristics, and the present study sug-
gested that patients with lymphovascular invasion may
have higher risk for relapse. Although the difference
was not significant, 40.0% of the patients showing
lymphovascular invasion had disease relapse, while 18.8%
of those without it experienced relapse (Figure 3, Table 6).
The present study had several limitations. It was
performed in a retrospective design, and the study vol-
ume was relatively small. Also, our database did not in-
clude information about the presence of some
uncommon histological components such as sarcoma-
tous differentiation coexistent with teratoma and poten-
tially having an impact on oncological outcomes [4,13].
Conclusions
In men with stage I seminoma, surveillance after orchi-
ectomy is a feasible option. Although further studies are
warranted, the present study suggested that tunica
albuginea involvement may be a risk factor associatedwith disease relapse in them. In men with stage I
nonseminoma and normalized markers after orchiec-
tomy, surveillance is also a feasible option, but those
with lymphovascular invasion may possibly be at high
risk for disease relapse.
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